Not found

Paolo Zanotti Fregonara, MD, PhD

Associate Research Professor of Neurology, Institute for Academic Medicine
Associate Research Member; Director, PET Core Facility, Research Institute
Houston Methodist
Weill Cornell Medical College


Positron Emission Tomography (PET) facility


Biography

Dr. Paolo Zanotti Fregonara earned his Medical Degree in 1998 and board certification in Nuclear Medicine in 2002 from the University of Milan, Italy. He earned a Master’s Degree in Radiobiology/Radioprotection in 2005 and a PhD in Medical Physics in 2009 from the University of Paris, France. He held appointments at University hospitals in Paris and Bordeaux, the Atomic Energy Commission PET center in Orsay, France, and the Molecular Imaging Branch (NIMH) in Bethesda, Maryland, before rejoining in 2016 the Houston Methodist Research Institute as the director of the PET core imaging lab and chair of the Radiation Safety Committee.

Areas Of Expertise

PET Kinetic modeling Dosimetry
Publications

A longitudinal study on deep brain stimulation of the medial forebrain bundle for treatment-resistant depression
Fenoy, AJ, Schulz, PE, Selvaraj, S, Burrows, CL, Zunta-Soares, G, Durkin, K, Zanotti-Fregonara, P, Quevedo, J & Soares, JC 2018, Translational psychiatry, vol. 8, no. 1, 111. DOI: 10.1038/s41398-018-0160-4

Decreased Cannabinoid CB1 Receptors in Male Tobacco Smokers Examined With Positron Emission Tomography
Hirvonen, J, Zanotti-Fregonara, P, Gorelick, DA, Lyoo, CH, Rallis-Frutos, D, Morse, C, Zoghbi, SS, Pike, VW, Volkow, ND, Huestis, MA & Innis, RB 2018, Biological Psychiatry, vol. 84, no. 10, pp. 715-721. DOI: 10.1016/j.biopsych.2018.07.009

Patient-specific computational model and dosimetry calculations for PET/CT of a patient pregnant with twins
Xie, T, Zanotti-Fregonara, P, Edet-Sanson, A & Zaidi, H 2018, Journal of Nuclear Medicine, vol. 59, no. 9, pp. 1451-1458. DOI: 10.2967/jnumed.117.205286

Head-to-head comparison of 11C-PBR28 and 18F-GE180 for quantification of the translocator protein in the human brain
Zanotti-Fregonara, P, Pascual, B, Rizzo, G, Yu, M, Pal, N, Beers, D, Carter, R, Appel, SH, Atassi, N & Masdeu, JC 2018, Journal of Nuclear Medicine, vol. 59, no. 8, pp. 1260-1266. DOI: 10.2967/jnumed.117.203109

Advantages and limits of targeted radionuclide therapy with somatostatin antagonists
Hindie, E, Morgat, C, Zanotti-Fregonara, P, Haissaguerre, M, Bordenave, L & Tabarin, A 2018, Journal of Nuclear Medicine, vol. 59, no. 3, pp. 546-547. DOI: 10.2967/jnumed.117.202630

Somatostatin antagonists for radioligand therapy of nonendocrine tumors
Hindie, E, Zanotti-Fregonara, P & Morgat, C 2018, Journal of Nuclear Medicine, vol. 59, no. 3. DOI: 10.2967/jnumed.117.199158

Building a database for brain 18 kDa translocator protein imaged using [11C]PBR28 in healthy subjects
Paul, S, Gallagher, E, Liow, JS, Mabins, S, Henry, K, Zoghbi, SS, Gunn, RN, Kreisl, WC, Richards, EM, Zanotti-Fregonara, P, Morse, CL, Hong, J, Kowalski, A, Pike, VW, Innis, RB & Fujita, M 2018, Journal of Cerebral Blood Flow and Metabolism. DOI: 10.1177/0271678X18771250

PET radioligand binding to translocator protein (TSPO) is increased in unmedicated depressed subjects
Richards, EM, Zanotti-Fregonara, P, Fujita, M, Newman, L, Farmer, C, Ballard, ED, Machado-Vieira, R, Yuan, P, Niciu, MJ, Lyoo, CH, Henter, ID, Salvadore, G, Drevets, WC, Kolb, H, Innis, RB & Zarate, CA 2018, EJNMMI Research, vol. 8, 57. DOI: 10.1186/s13550-018-0401-9

New fetal radiation doses for18F-FDG based on human data
Zanotti-Fregonara, P & Stabin, MG 2017, Journal of Nuclear Medicine, vol. 58, no. 11, pp. 1865-1866. DOI: 10.2967/jnumed.117.195404

On the role of interim fluorine-18–labeled fluorodeoxyglucose positron emission tomography in early-stage favorable hodgkin lymphoma
Hindié, E, Mesguich, C & Zanotti-Fregonara, P 2017, Journal of Clinical Oncology, vol. 35, no. 24, pp. 2851-2852. DOI: 10.1200/JCO.2017.73.8369

Linear no-threshold hypothesis at the hospital: When raDioprotection becomes a nosocomial hazard
Zanotti-Fregonara, P & HinDie, E 2017, Journal of Nuclear Medicine, vol. 58, no. 8, pp. 1355. DOI: 10.2967/jnumed.117.190983

Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging
Zanotti-Fregonara, P, Morgat, C, Champion, C & Hindié, E 2017, European Journal of Nuclear Medicine and Molecular Imaging, pp. 1-2. DOI: 10.1007/s00259-017-3667-7

Performing nuclear medicine examinations in pregnant women
Zanotti-Fregonara, P & Hindie, E 2017, Physica Medica. DOI: 10.1016/j.ejmp.2017.05.043

Standardized input function for 18F-FDG PET studies in mice: A cautionary study
Meyer, M, Le-Bras, L, Fernandez, P & Zanotti-Fregonara, P 2017, PLoS ONE, vol. 12, no. 1, e0168667. DOI: 10.1371/journal.pone.0168667

Re: 13I and 124I accumulation in a thymic cyst
Zanotti-Fregonara, P & Hindie, E 2017, Clinical nuclear medicine, vol. 42, no. 7, pp. 576. DOI: 10.1097/RLU.0000000000001700

18F-FDG Imaging of Chronic Inflammation Associated With Promontofixation of the Uterus
Meyer, M, Fernandez, P & Zanotti-Fregonara, P 2017, Clinical nuclear medicine, vol 42, no. 1, pp. 42-43.

18F-FDG Imaging of Chronic Inflammation Associated With Promontofixation of the Uterus
Meyer, M, Fernandez, P & Zanotti-Fregonara, P 2017, Clinical nuclear medicine, vol. 42, no. 1, pp. 42-43.

Generalization of endothelial modelling of TSPO PET imaging: Considerations on tracer affinities
Rizzo, G, Veronese, M, Tonietto, M, Bodini, B, Stankoff, B, Wimberley, C, Lavisse, S, Bottlaender, M, Bloomfield, PS, Howes, O, Zanotti-Fregonara, P, Turkheimer, FE & Bertoldo, A 2017, Journal of Cerebral Blood Flow and Metabolism. DOI: 10.1177/0271678X17742004

Re: 131I and 124I Accumulation in a Thymic Cyst
Zanotti-Fregonara, P & Hindie, E 2016, Clinical nuclear medicine. DOI: 10.1097/RLU.0000000000001520

18F-FDG Imaging of Chronic Inflammation Associated With Promontofixation of the Uterus
Meyer, M, Fernandez, P & Zanotti-Fregonara, P 2017, Clinical Nuclear Medicine, vol 42, no. 1, pp. 42-43. DOI: 10.1097/RLU.0000000000001420